Land: Verenigde Staten
Taal: Engels
Bron: NLM (National Library of Medicine)
Atropine Sulfate (UNII: 03J5ZE7KA5) (Atropine - UNII:7C0697DR9I)
Henry Schein, Inc.
INTRAVENOUS
PRESCRIPTION DRUG
Atropine Sulfate Injection, USP, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. None. 8.1 Pregnancy Animal reproduction studies have not been conducted with atropine. It also is not known whether atropine can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. 8.3 Nursing Mothers Trace amounts of atropine was found in breast milk. The clinical impact of this is not known. 8.4 Pediatric Use Recommendations for use in pediatric patients are not based on clinical trials. 8.5 Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of d
Atropine Sulfate Injection, USP, 0.1 mg/mL, is a clear and colorless solution available in 5 mL and 10 mL single-dose glass vials. Each vial is co-packaged with an injector, which together make a LifeShield Abboject Glass Syringe. It is supplied in the following presentations: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). [See USP Controlled Room Temperature.]
unapproved drug other
ATROPINE SULFATE- ATROPINE SULFATE INJECTION, SOLUTION HENRY SCHEIN, INC. _Disclaimer: This drug has not been found by FDA to be safe and effective, and this_ _labeling has not been approved by FDA. For further information about unapproved_ _drugs, click here._ ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION ATROPINE SULFATE 0.1 MG/ML INJECTION, USP 10 ML PREFILLED SYRINGE HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ATROPINE SULFATE INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ATROPINE SULFATE INJECTION.ATROPINE SULFATE INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1960 INDICATIONS AND USAGE (1) DOSAGE AND ADMINISTRATION (2) DOSAGE FORMS AND STRENGTHS 0.1 mg/mL injection in LifeShield™ Abboject™ Glass Syringe (3) (3) CONTRAINDICATIONS None. (4) (4) WARNINGS AND PRECAUTIONS Tachycardia (5.1) (5) (5) Glaucoma (5.2) (5) (5) Pyloric obstruction (5.3) (5) (5) Worsening urinary retention (5.4) (5) (5) Viscid bronchial plugs (5.5) (5) (5) DRUG INTERACTIONS Mexiletine: Decreases rate of mexiletine absorption. (7.1) (7) (6) Revised: 3/2018 (6) REVISED: 10/2023 FULL PRESCRIBING INFORMATION: CONTENTS* INDICATIONS AND USAGE DOSAGE AND ADMINISTRATION DOSAGE FORMS AND STRENGTHS CONTRAINDICATIONS WARNINGS AND PRECAUTIONS DRUG INTERACTIONS USE IN SPECIFIC POPULATIONS OVERDOSAGE DESCRIPTION CLINICAL PHARMACOLOGY NONCLINICAL TOXICOLOGY HOW SUPPLIED * Sections or subsections omitted from the full prescribing information are not listed. FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE Atropine Sulfate Injection, USP, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. DOSAGE AND ADMINISTRATION 2.1 GENERAL ADMINISTRATION Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenev Lees het volledige document